ABSTRACT
Population based data on COVID-19 are urgently needed for informing policy decisions, yet few such studies are available anywhere, as most surveys rely on self-selected volunteers. In the Brazilian State of Rio Grande do Sul (population 11.3 million), we are carrying out fortnightly household surveys in nine of the largest cities. Multi-stage probability sampling was used in each city to select 500 households, within which one resident was randomly chosen for testing. The Wondfo lateral flow rapid test for detecting antibodies against SARS-CoV-2 has been validated in four different settings, including our own, with pooled estimates of sensitivity (84.8%, 95% CI 81.4%;87.8%) and specificity (99.0%, 95% CI 97.8%;99.7%), which are within the acceptable range for epidemiological studies. In the first wave of the study (April 11-13), 4,188 subjects were tested, of whom two were positive (0.0477%; 95% confidence interval (CI) 0.0058%;0.1724%). In the second round (Apr 25-27) there were six positive subjects (0.1333%; 95% CI 0.0489%;0.2900%). We also tested family members of positive index cases, and nine out of 19 had positive results. Testing of reported COVID-19 cases according to RT-PCR confirmed that the test was highly sensitive under field conditions. The epidemic is at an early stage in the State, as the first case was reported on Feb 28, and by Apr 30, 50 deaths were registered. Strict lockdown measures were implemented in mid-March, and our results suggest that compliance was high, with full or near full compliance rates of 79.4% in the first and 71.7% in the second round. As far as we know, this is the only large population anywhere undergoing regular household serological surveys for COVID-19. The results show that the epidemic is at an early phase, and findings from the next rounds will allow us to document time trends and propose Public Health measures.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
This work started through the Data Committee created by the State of Rio Grande do Sul government to fight the COVID-19 pandemics. The tests used in the study have been provided by the Brazilian Ministry of Health. Funding for data collection was provided by UNIMED Porto Alegre, Instituto Cultural Floresta and Instituto Serrapilheira.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Joint last authors
Funding: This work started through the Data Committee created by the State of Rio Grande do Sul government to fight the COVID-19 pandemics. The tests used in the study have been provided by the Brazilian Ministry of Health. Funding for data collection was provided by UNIMED Porto Alegre, Instituto Cultural Floresta and Instituto Serrapilheira.
Data Availability
The full dataset will be made publicly available no longer than 30 days after each wave of data collection.
